Pfizer initiates phase I trial for Hemophilia drug

Monday, January 9, 2012 09:36 AM

Pfizer has initiated a phase I clinical trial for PF-05280602, an engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.

"We are very excited to see the lead candidate from Catalyst’s hemostasis franchise advance into human clinical trials," said Nassim Usman, Ph.D., CEO of Catalyst Biosciences.

The drug has been engineered to provide improved acute and prophylactic treatment for hemophilia A and B patients with inhibitors. The initiation of phase I clinical trials triggered $7 million in milestone payments to Catalyst Biosciences from Pfizer.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs